AIM
AMEXAIM ImmunoTech Inc.
SectorHealth CareIndustryBiotechnology: Biological Products (No Diagnostic Substances)
Price$0.26+0.00 (+0.00%)
02:30 PM07:45 PM
News · 26 weeks72-50%
2026-01-182026-07-12
Mix3790d
- SEC Filings22(59%)
- Other13(35%)
- Offering2(5%)
Latest news
25 items- SECAIM ImmunoTech Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - AIM ImmunoTech Inc. (0000946644) (Filer)
- SECSEC Form S-8 filed by AIM ImmunoTech Inc.S-8 - AIM ImmunoTech Inc. (0000946644) (Filer)
- PRAIM ImmunoTech Announces Release of New CEO Corner Segment Highlighting Growing Momentum Across Pancreatic Cancer ProgramAccess it here OCALA, Fla., July 07, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") today announced the release of its latest CEO Corner segment, featuring Chief Executive Officer Thomas Equels discussing the Company's continued momentum in pancreatic cancer and the significant clinical, strategic and operational milestones positioning Ampligen® for its next stage of development. In the segment, Mr. Equels highlights the urgent unmet need facing patients with pancreatic cancer, reviews recent progress across the Company's DURIPANC Phase 2 clinical program evaluating Ampligen® (rintatolimod) in combination with AstraZeneca's Imfinzi® (durvalumab), and dis
- SECSEC Form DEF 14A filed by AIM ImmunoTech Inc.DEF 14A - AIM ImmunoTech Inc. (0000946644) (Filer)
- SECSEC Form 424B3 filed by AIM ImmunoTech Inc.424B3 - AIM ImmunoTech Inc. (0000946644) (Filer)
- PRAIM ImmunoTech Accelerates Toward Potential Pivotal Pancreatic Cancer Program as Ampligen Continues to Advance Through Key Clinical MilestonesOCALA, Fla., June 24, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") today highlighted the significant progress achieved across its pancreatic cancer development program and outlined a series of anticipated milestones that position the Company for what management believes could be a pivotal period in its evolution as a clinical-stage oncology company. At the center of AIM's strategy is Ampligen® (rintatolimod), the Company's proprietary TLR3 agonist immunotherapy, which is being evaluated in the ongoing Phase 2 DURIPANC study in combination with AstraZeneca's PD-L1 inhibitor Imfinzi® (durvalumab) for the treatment of metastatic pancreatic cancer. Pancrea
- SECSEC Form EFFECT filed by AIM ImmunoTech Inc.EFFECT - AIM ImmunoTech Inc. (0000946644) (Filer)
- PRAIM ImmunoTech to Present in the Webull Corporate Connect Webinar SeriesOCALA, Fla., June 22, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") today announced that it will present in the Webull Corporate Connect Webinar Series being held virtually June 24-25, 2026. Details for the presentation are as follows: Date and Time: Wednesday, June 24, 2026 at 2:40 – 3:00 PM ETPresenter: Thomas Equels, AIM ImmunoTech’s Chief Executive Officer Registration Link: HERE About Webull Financial Webull Corporation (NASDAQ:BULL) owns and operates Webull, a leading digital investment platform built on next-generation global infrastructure. Through its global network of licensed brokerages, Webull offers investment services in 16 markets ac
- SECSEC Form 424B3 filed by AIM ImmunoTech Inc.424B3 - AIM ImmunoTech Inc. (0000946644) (Filer)
- PRAIM ImmunoTech Achieves Clinical Milestone as Final Subject Receives First Dose in Phase 2 DURIPANC Study in Metastatic Pancreatic CancerOCALA, Fla., June 18, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") today announced that the final subject has received their first dose in the Phase 2 DURIPANC clinical trial evaluating Ampligen® (rintatolimod) in combination with AstraZeneca's anti-PD-L1 immune checkpoint inhibitor Imfinzi® (durvalumab) for the treatment of metastatic pancreatic cancer. With this final subject, Primary Endpoint analysis is anticipated to begin in December 2026 and topline results are anticipated in Q1 2027. DURIPANC's primary endpoint is Clinical Benefit Rate ("CBR"), defined as the proportion of patients achieving stable disease, partial response or complete response
- SECSEC Form S-1 filed by AIM ImmunoTech Inc.S-1 - AIM ImmunoTech Inc. (0000946644) (Filer)
- SECSEC Form EFFECT filed by AIM ImmunoTech Inc.EFFECT - AIM ImmunoTech Inc. (0000946644) (Filer)
- SECSEC Form PRE 14A filed by AIM ImmunoTech Inc.PRE 14A - AIM ImmunoTech Inc. (0000946644) (Filer)
- SECAIM ImmunoTech Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - AIM ImmunoTech Inc. (0000946644) (Filer)
- PRAIM ImmunoTech Regains NYSE American Compliance, Company Resolves Stockholder Equity DeficiencyOCALA, Fla., June 15, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) ("AIM," or the "Company"), an immuno-pharma company focused on the development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, today announced that it has received written notice from the NYSE American that AIM has regained compliance with NYSE American's continued listing standards related to stockholders' equity. On May 7, 2026, the Company entered into a warrant exercise inducement offer letter agreement with certain a holder of existing warrants, pursuant to which the holders agreed to exercise their warrants in cash at a reduced exercise price for aggregate gross pr
- SECSEC Form 8-K filed by AIM ImmunoTech Inc.8-K - AIM ImmunoTech Inc. (0000946644) (Filer)
- SECSEC Form 424B5 filed by AIM ImmunoTech Inc.424B5 - AIM ImmunoTech Inc. (0000946644) (Filer)
- PRAIM ImmunoTech Announces $2.65 Million Financing Priced At-Market under NYSE American RulesOCALA, Fla., June 09, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company"), today announced that it has entered into definitive agreements for a registered direct offering and concurrent private placement priced at-the-market under NYSE American rules for gross proceeds of approximately $2.65 million, before deducting placement agent commissions and other offering expenses. Ladenburg Thalmann & Co. Inc. is acting as the exclusive placement agent for the offering. The offering is expected to close on or about June 10, 2026, subject to the satisfaction of customary closing conditions. In the registered direct offering, the Company will issue and sell 2,554,119
- SECSEC Form S-1 filed by AIM ImmunoTech Inc.S-1 - AIM ImmunoTech Inc. (0000946644) (Filer)
- PRAIM ImmunoTech Reports Positive Mid-Year Interim Clinical Progress from Phase 2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca's Imfinzi® (durvalumab) for the Treatment of Pancreatic CancerOCALA, Fla., June 08, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") today reported positive progress in a mid-year update from the ongoing Phase 2 clinical study evaluating AIM's drug Ampligen® (rintatolimod) combined with AstraZeneca's anti-PD-L1 immune checkpoint inhibitor Imfinzi® (durvalumab) in the treatment of metastatic pancreatic cancer patients with stable disease post-FOLFIRINOX standard of care (the "DURIPANC" study) (see: ClinicalTrials.gov NCT05927142). See: DURIPANC, 2026 Mid-Year Interim Clinical Progress Update AIM recently announced enrollment of the final patient in the clinical trial, barring any disqualifying pre-treatment circumstan
- SECAIM ImmunoTech Inc. filed SEC Form 8-K: Regulation FD Disclosure8-K - AIM ImmunoTech Inc. (0000946644) (Filer)
- PRAIM ImmunoTech Releases Virtual Investor 'What This Means' Video Segment Discussing Ampligen's Potential in Ebola Virus Disease PreparednessVideo segment examines current Ebola outbreak concerns, unmet need surrounding the Bundibugyo strain and Ampligen's previously published antiviral research Discussion highlights Ampligen's immune-modulating mechanism, prior Biosafety Level 4 findings and potential applicability across emerging viral threats New Ebola-focused corporate presentation highlighting Ampligen's antiviral research and preparedness potential is now accessible here Access the ‘What This Means' video segment here OCALA, Fla., June 04, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") today announced the release of a Virtual Investor "What This Means" video segment featuring AIM Chie
- PRAIM ImmunoTech Completes Phase 2 DURIPANC Enrollment Milestone Ahead of Schedule, Advancing Ampligen Toward Critical Pancreatic Cancer Clinical MilestonesOCALA, Fla., June 01, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") today announced a significant milestone in its pancreatic cancer development program, with enrollment of the final subject, barring disqualifying pre-treatment circumstances. The final planned subject is scheduled for treatment in mid-June, surpassing the Company's original enrollment target of July 2026 in the Phase 2 clinical trial of AIM's drug Ampligen® (rintatolimod) combined with AstraZeneca's anti-PD-L1 immune checkpoint inhibitor Imfinzi® (durvalumab) in the treatment of metastatic pancreatic cancer patients with stable disease post-FOLFIRINOX standard of care (the "DURIPANC" stud
- PRAIM ImmunoTech Announces Emerging Ebola Opportunity for Ampligen Amid Escalating Global Health Concerns and WHO Emergency DeclarationPreviously published Biosafety Level 4 pre-clinical study showed 100% survival with early treatment following infection in a mouse model following lethal doses of Ebola Company to release Virtual Investor "Ebola: What This Means" Segment on June 4th at 9:00 AM ET OCALA, Fla., May 27, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company"), an immuno-pharma company focused on the development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, today announced it will release an on-demand video presentation detailing important previously published pre-clinical findings supporting the potential role of its lead drug Ampligen® (rin
- SECAIM ImmunoTech Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits8-K - AIM ImmunoTech Inc. (0000946644) (Filer)
AIM FAQ
5 questionsWhat does AIM ImmunoTech Inc. do?
AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viruses, and immune-deficiency disorders in the United States. The company's products include Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, prostate and pancreatic cancer, myalgic encephalomyelitis, Hepatitis B, and HIV. The company also provides...Where does AIM stock trade?
AIM ImmunoTech Inc. (AIM) is listed on AMEX.What sector and industry is AIM in?
AIM ImmunoTech Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.What companies are similar to AIM?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.), BIIB (Biogen Inc.). Compare AIM side-by-side with any of them on Quantisnow.How can I track AIM on Quantisnow?
Quantisnow aggregates AIM ImmunoTech Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow AIM to receive live email and push alerts on every new disclosure.